OMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxThe OMNIRAY trial will be investigating LY4257496, a novel radioligand therapy and it is set to begin in August 2025. This phase 1a/1b, multicenter, open-label study aims to establish the safety, tolerability and dosimetry of LY4257496 in adult patients bearing advanced solid tumors that express the gastrin-releasing peptide receptor (GRPR). The trial proposes a two-part […]
Immunotherapy Drug Eradicates Aggressive Cancers in Clinical Trial
/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: HLD-0915 Advances with FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTrial to Test If Intermittent Fasting Can Boost Prostate Cancer Treatment Efficacy
/in Clinical Trial, Localized, Metastatic, Phase 1, Phase 2/by MaxPhase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026